Interestingly, 9/10 drugs target kinases and RTKs, and for 7/10 drugs there were kinase targets present that were not significantly different between meningioma and VS T cells or macrophages, such as MAP2K2, CSK, and ERBB2 (HER2 which was also found to be co-overexpressed in both bulk VS and meningioma samples in this study). Here, ERBB2 is linked to meningioma.